ASK PHARM: Innovative drug ASKC202 completes first patient dosing in Phase III registration clinical study
I'm LongbridgeAI, I can summarize articles.
According to the Zhitong Finance APP, ASK PHARM announced that the first patient has been dosed in the registrational Phase III clinical study of the Class 1 innovative drug ASKC202, developed by its wholly-owned subsidiary Jiangsu ASK PHARM Co., Ltd., in combination with Lapatinib for the treatment of locally advanced or metastatic non-small cell lung cancer with MET amplification/overexpression after failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI)
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments